Back to search results

Observational Study of Intestinal Immunity in Neurologic Disease

This observational study is looking at how immune cells in your gut (gastrointestinal tract) might be connected to diseases like Multiple Sclerosis, Parkinson's Disease, and REM Sleep Behavior Disorder. Researchers want to understand the specific roles these immune cells play in these conditions. You could join if you are 18 or older and are already scheduled for a colonoscopy (a procedure to look at your colon) or are willing to have one for the study. The main goal is to understand the immune cells in the lining of your gut, which will be studied over an average of five years. This study is not testing a new drug, but rather observing how your body works.

Study design
This is an observational study planning to enroll 100 participants. It is not testing a specific treatment, but rather observing natural processes.
What's involved
You would undergo a colonoscopy, and possibly an upper endoscopy, to provide tissue biopsies from your gastrointestinal tract.
Compensation
Not stated in the trial record.
Follow-up
Your immune cells will be characterized through study completion, an average of 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06329453

Intestinal Immunity in Neurologic Disease

Recruiting
Not specifiedAges 18–99Observational
Yale University
~100 participants
Updated 2026-05-27 on ClinicalTrials.gov
What's tested:Colon Tissue Biopsy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Characterization of immune cells from the gastrointestinal mucosa
Measured over Through study completion, an average of 5 years

Conditions

Multiple Sclerosis
Parkinson Disease
REM Sleep Behavior Disorder

Explore related trials

Multiple SclerosisParkinson DiseaseREM sleep behavior disorder

NCT06329453

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Yale MS Clinic

    North Haven, Connecticutstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Erin Longbrake · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Cynthia Marques
[email protected]
2032876100
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 and up
Recommended to under a screening colonoscopy (+/- upper endoscopy) as part of standard of care. This includes healthy individuals as well as those with neurologic and/or autoimmune diseases. OR
Willing to undergo research colonoscopy (+/- upper endoscopy) for research

Exclusion

Currently pregnant. Women of childbearing potential would perform a point of care urine pregnancy test prior to colonoscopy/endoscopy.
Known or suspected, chronic inflammatory gastrointestinal disease (e.g. inflammatory bowel disease)
Known, acute or chronic infections
Systemic antibiotic (PO or IV) use within 3 months of colonoscopy
Systemic corticosteroid use (equivalent of prednisone 10 mg per day or higher for \>5 days) within 2 weeks of colonoscopy
Malignancy, diagnosed or treated within the last 5 years
Probiotic use within 2 weeks of procedure
History of major GI surgery (e.g. colon resection, gastric bypass)
Bleeding disorder, or on anticoagulant medication
Other medical condition that, in the judgement of the investigator, would lead to higher-than-expected risks of biopsy
Allergy to MAC anesthesia or other drugs used pursuant to standard of care for biospecimen collection

What this trial measures

  • Characterization of immune cells from the gastrointestinal mucosaThrough study completion, an average of 5 years

    Gastrointestinal mucosa cells will be characterized using sRNA measured through high-throughput sequencing with quantitative polymerase chain reaction (qPCR) validation.